CT-388

all catalysts(0)

nothing on the calendar yet

News(7)

• STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program
  Eli Lilly and Novo Nordisk were already benefitting a great deal from the Trump administration's pilot program covering obesity drugs for seniors at a price of $245 a month. It…
  stat · 11d ago
• Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
  The mid-stage readout is one link in a chain of catalysts that analysts were watching for this year from Roche’s metabolic pipeline, which features assets from the $2.7 billion acquisition of Carmo…
  biospace · 11d ago
• Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
  A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has hit its primary endpoints, painting the drug candidate as a potential treatment for people with type 2 diabetes and overweight or obes…
  fiercebiotech · 11d ago
• Roche pours $750M into Oregon manufacturing plant as obesity push expands
  After committing $2 billion to a new North Carolina facility to boost capacity for its next-gen obesity candidates, Roche's Genentech is putting down more cash to expand a device fill-finish site i…
  biospace · 1mo ago
• Roche cans one Carmot obesity asset as another shows best-in-class potential
  Acmopatide met the main goal of a Phase 2 study in type 1 diabetes, but Roche is axing the investigational drug to prioritize enicepatide for weight loss, type 2 diabetes and cardiovascular outcome…
  biospace · 2mo ago
• Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
  Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…
  biospace · 2mo ago
• ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
  At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.
  biopharma_dive · 3mo ago